Source: Annual Congress 2002 - Smoking prevention and cessation
Disease area: Airway diseases

Abstract

OBJECTIVE:to demonstrate the efficacy and tolerability of bupropion SR (Zyban™;) versus placebo in smokers with cardiovascular disease (CVD).
METHODS:629 motivated to quit smokers with CVD, who smoked >10 cigarettes/day were randomised. Subjects received bupropion SR 150mg bid or placebo for 7 weeks as out-patients with weekly motivational support and follow-up to Week 52.
RESULTS:Four week continuous abstinence (weeks 4-7) was more than double in the bupropion SR group, 43%, versus placebo, 19% (p<0.001, Odds Ratio 3.27; 95%CI 2.24-4.84). Continuous abstinence from Weeks 4-52 continued to be more than double for bupropion SR versus placebo (22% vs.9%, p<0.001, OR 2.78; 95%CI 1.70-4.63). From Week 3 through Week 52 weekly point prevalence abstinence for bupropion SR was significantly higher versus placebo (Week 52: 27% vs. 12%, p<0.001, OR 2.87; 95%CI 1.83-4.57). Common adverse events for both treatment groups were insomnia, dry mouth, nausea and dizziness (incidence greater in the active arm) and headache (same incidence in both groups). Analysis of the blood pressure data did not show any statistically or clinically significant effect of treatment.
CONCLUSIONS:there is clearly a role for bupropion SR in smoking cessation for smokers with CVD, with more than twice as many bupropion SR subjects being abstinent at one year, with an adverse event profile similar to that seen in studies conducted in a general population.

Rating:

Share or cite this content

Citations should be made in the following way:
H. McRobbie, H. Brath, C. Astbury, A. Hider, R. Sweet (London, Greenford, United Kingdom; Vienna, Austria). Bupropion hydrochloride sustained release (SR) is an effective and well tolerated aid to smoking cessation in smokers with cardiovascular disease. 12 month follow-up phase data (ZYB40014). Eur Respir J 2002; 20: Suppl. 38, 3822

Member's Comments

No comment yet.

Related content which might interest you: Bupropion hydrochloride sustained release (SR) is an effective and well tolerated aid to smoking cessation in smokers with cardiovascular disease - a multicountry study Source: Eur Respir J 2001; 18: Suppl. 33, 12s Year: 2001 Bupropion hydrochloride sustained release (SR) is an effective and well tolerated aid to smoking cessation in a healthcare professionals population - a multicountry study Source: Eur Respir J 2001; 18: Suppl. 33, 166s Year: 2001 Bupropion hydrochloride (Zyban™) is effective and well tolerated as an aid to smoking cessation - a multicountry study Source: Eur Respir J 2001; 18: Suppl. 33, 11s Year: 2001 The smoking cessation efficacy of bupropion hydrochloride sustained release tablets (BUP SR) versus placebo (PBO) in smokers with chronic obstructive pulmonary disease (COPD) with respect to age, gender, pack-year history and COPD Source: Eur Respir J 2001; 18: Suppl. 33, 192s Year: 2001 The efficacy of bupropion hydrochloride sustained release (SR) for smoking cessation is consistent in placebo-controlled studies Source: Eur Respir J 2002; 20: Suppl. 38, 579s Year: 2002 Smoking cessation decreases the risk to develop COPD; a 25 yr follow-up study Source: Eur Respir J 2005; 26: Suppl. 49, 434s Year: 2005 Smoking cessation and prevention Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-48-0, page=242 Year: 2006 In respiratory patients short term complete abstinence from smoking does not depend on the stage of change Source: Annual Congress 2005 - Smoking cessation in respiratory diseases: methods and results Year: 2005 Fluticasone/salmeterol combination (FSC) is safe and provides effective long-term (52 week) control in the management of patients with persistent asthma (PA) Source: Eur Respir J 2001; 18: Suppl. 33, 176s Year: 2001 Relapse rates following different types of medication treatment through a smoking cessation program Source: Annual Congress 2006 - How to treat tobacco smokers Year: 2006 Pharmacological treatment for smoking cessation Source: Eur Respir Mon; 2008: 42: 74–97 Year: 2008 Success rates of smoking cessation program using bupropion therapy: a 1-year experience Source: Eur Respir J 2005; 26: Suppl. 49, 388s Year: 2005 Comparison of efficiacy and success of hypnotherapy and medical drugs to quit smoking. First 6 months results Source: Annual Congress 2009 - Epidemiology of smoking and smoking cessation Year: 2009 Varenicline is a cost-effective pharmacotherapy in smoking cessation of nicotine dependent patients with mild to moderate COPD Source: Annual Congress 2012 - Looking at the cost effectiveness of asthma and COPD treatment by novel drugs and improved management Year: 2012 Psychology rehabilitation (PR): influence on the course of disease, psychological status (PS) and the smoking cessation rate (SCR) in patients with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 67s Year: 2004 Efficacy of bupropion SR in a smoking cessation programme for heavy smokers: preliminary results Source: Eur Respir J 2001; 18: Suppl. 33, 167s Year: 2001 Intervention study to evaluate effectiveness of integrated therapy (varenicline plus montivational interviewing) for smoking cessation in diabetic patients: Source: Annual Congress 2012 - Smoking tobacco: from second hand to earthquake Year: 2012 Smoking cessation and COPD Source: Eur Respir Rev 2013; 22: 37-43 Year: 2013 Evaluation of prolonged bupropion treatment as an aid in smoking cessation Source: Eur Respir J 2002; 20: Suppl. 38, 611s Year: 2002